Pharmaceutical launches sales growth
STO-REC-STAT01M2KJT2 National
48.3%
Global · Q2 2026
Pharmaceutical launches sales growth came in at 48.3% in Q2 2026 (Sanofi).
- Publisher
- Sanofi
- Authority tier
- T2 National
- Locator
- Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven mostly by Ayvakit, ALTUVIIIO, and Sarclisa
Verbatim extraction verified: The figure 48.3% is directly attested in the quoted passage (Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9
- MLA
- Sanofi. "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded." 2026, https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9.
- Chicago
- Sanofi. "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded." 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9.
- BibTeX
- @misc{sanofi2026pharmaceuticalbjmgf9, author = {{Sanofi}}, title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9}, note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- Sanofi · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
- Type
- Press release
- Published
- 30 July 2026
- Locator
- Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 15 September 2026
- Archival URI
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9